DNPUF (Sumitomo Pharma Co) Debt-to-Asset : 0.27 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DNPUF Sumitomo Pharma Co Ltd DNPUF
60 GF Score
Price $9.27
GF Value $5.65
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co Debt-to-Asset?

Sumitomo Pharma Co DNPUF 60 Debt-to-Asset is 0.27 as of Mar. 2026. GuruFocus rates DNPUF with a GF Score™ of 60/100 and a GF Value™ of $5.65 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sumitomo Pharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $240 Mil. Sumitomo Pharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $1,128 Mil. Sumitomo Pharma Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2026 was $5,070 Mil. Sumitomo Pharma Co's debt to asset for the quarter that ended in Mar. 2026 was 0.27.

Sumitomo Pharma Co  (OTCPK:DNPUF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sumitomo Pharma Co Debt-to-Asset Related Terms

Sumitomo Pharma Co Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Sumitomo Pharma Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sumitomo Pharma Co Debt-to-Asset Chart

Sumitomo Pharma Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.30 0.46 0.41 0.27

Sumitomo Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.34 0.32 0.27 0.19

DNPUF vs ZTS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sumitomo Pharma Co Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sumitomo Pharma Co's Debt-to-Asset falls into.


DNPUF
60GF Score
Sumitomo Pharma Co Ltd DNPUF
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sumitomo Pharma Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sumitomo Pharma Co's Debt-to-Asset for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(240.291 + 1128.39) / 5070.313
=0.27

Sumitomo Pharma Co's Debt-to-Asset for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(240.291 + 1128.39) / 5070.313
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.27 mean?
Sumitomo Pharma Co (DNPUF) has a Debt-to-Asset of 0.27 as of Mar. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Sumitomo Pharma Co and its competitors.
Is Sumitomo Pharma Co's Debt-to-Asset too high?
Sumitomo Pharma Co's current Debt-to-Asset is 0.27. Overall, Sumitomo Pharma Co has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sumitomo Pharma Co's Debt-to-Asset compare to ZTS?
Sumitomo Pharma Co's Debt-to-Asset of 0.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Sumitomo Pharma Co and its competitors. Sumitomo Pharma Co's current Debt-to-Asset is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sumitomo Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Sumitomo Pharma Co (DNPUF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.65, compared to a current price of $9.27 — trading 64.1% above its estimated fair value. The current Debt-to-Asset is 0.27. Sumitomo Pharma Co's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Sumitomo Pharma Co (DNPUF), the current Debt-to-Asset is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sumitomo Pharma Co (DNPUF) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of $9.27 is trading 64.1% above its estimated GF Value™ of $5.65. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for DNPUF:

  • Debt-to-Asset: 0.27
  • GF Value™: $5.65 vs. price of $9.27 (64.1% above fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the DNPUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
60GF Score

Get the complete analysis for DNPUF

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.27
Price
$5.65
GF Value